HeartBeam, Inc. Q4 FY2025 earnings call

Overview of HeartBeam system and core technology; Brian Humbarger provided overview of limited commercial launch focusing on concierge and preventive cardiology practices with target price per patient $500 to $1,000; updates on heart attack detection with Align ACS study underway; unveiling of 12-lead patch working prototype and its potential to disrupt ambulatory cardiac monitoring market; AI initiatives with strategic collaboration with Mount Sinai to advance algorithms for heart attack assessment and wellness/clinical algorithms; major milestones achieved including FDA clearance, hiring CCO, signing collaboration with ClearCardio, initiating pilot study, completing patch prototype, and signing Mount Sinai collaboration.

No specific detailed financial performance data for product segments in absolute terms and revenue contribution % provided in the transcript; focuses on business progress and initiatives rather than detailed financial segment performance.

2026 baseline operating cash outflows expected at approximately $14 million; incremental investments tied to milestones add $3 million to $5 million to cost profile, resulting in gross operating cash outflows of approximately $17 million to $19 million for 2026; first half of 2026 steps up slightly due to clinical trials and patch developments; expectation of significant advancement on multiple fronts in 2026.

Forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially; risks related to regulatory approval timelines, market adoption of products, competition in the cardiac monitoring market, and uncertainties in achieving expected financial milestones.

Q: About Align ACS study timelines and patch initiatives, A: Align ACS study to enroll ~100 patients in ER, expect to complete by end of Q3 2026 to inform pivotal study; patch expected to be 510K, discussions ongoing with partners on go-to-market strategy.

Q: On commercialization strategy, A: Focus on anchor accounts like ClearCardio for proof points, then scale to larger concierge market; pricing includes reader service, and reimbursement is part of long-term vision.

Q: On Align ACS study accuracy and use case, A: Study aims to show similarity to 12-lead ECG in emergency room, focus on speeding up patient action time; accuracy within margin of error similar to 12-lead.

Q: On Mount Sinai alliance, A: Known Mount Sinai folks for a while, mutual respect led to deeper alliance; open to other similar alliances.

Q: On sales team and cardiologist excitement, A: Initially lean team for strategic accounts, will expand as scaling; cardiologists excited about 12-lead synthesized ECG's quality and clinical value.